Successful treatment of cutaneous leishmaniasis unresponsive to conventional drugs with itraconazole
DOI:
https://doi.org/10.66344/jpad.v32i2.1889Abstract
Leishmaniasis is a disease caused by a parasite of Leishmania Genus, transmitted by prick of an infected sandfly. The disease presents clinically with cutaneous, mucocutaneous or visceral form, depending upon the type of infective species and the immune status of the person. Antimonial drugs are first line of treatment for all clinical forms. Amphotericin B is second choice drug. We report a young male with cutaneous leishmaniasis unresponsive to conventional drugs successfully treated with itraconazole.
References
1. Wolf K, Johnson RA, Saavedra AP. Systemic parrasitic infections. Leishmaniasis. In: Fitzpatrick TB, ed. Color Atlas and Synopsis of Clinical Dermatology, 7th edn. USA: McGraw-Hill Companies, Inc. 2013; 721-5.
2. James WD, Berger TJ, Elston DM. Parasitic infestatiions,stings and bites. leishmaniasis. In: Andrews, ed. Diseases of the Skin, Clinical Dermatology, 10th edn. Canada: Elsevier Inc. 2006; 422-8.
3. Consigli J, Danielo C. Cutaneous leishmaniasis: successful treatment with itraconazole. Int J Dermatol. 2006;45:46-9.
4. Vaden Bossche H. Cytochrome p-450: target of itraconazole. Drug Dev Res. 1986;8:287-98.
5. Bennet JE. Agentes antimicrobianos. Agentes antimicoticos. In: Goodman GA, Hall TW, Nies AS, Taylor P, eds. Las bases farmacologicas de la terapéutica, 8th edn. Mexico DF: Panamericana, 1991; 1128-43.
6. Nassiri-Kashani M, Firoze A, et al. A randomized, double- blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishminiasis. J Euro Acad Dermatol Venerol. 2005;19(1):80-3.
7. Amato V, Padilha A, Nicodemo A, et al. Use of itraconazole in the treatment of mucocutaneous leishmaniasis: a pilot study. Int J Infect. 2000;4:153-7.
8. Dogra J, Saxena VN. Itraconazole and leishmaniasis: a randomized double-blind trial in cutaneous disease. Int J Parasitol. 1996;26:1413–5.
9. Momeni AZ, Jalayer T, Emamjomeh M, et al. Treatment of cutaneous leishmaniasis with itraconazole. Randomized double-blind study. Arch Dermatol. 1996;132:784–6.
10. Dogra J, Aneja N, Lal BB, et al. Cutaneous leishmaniasis in India. Clinical experience with itraconazole (R51 211 Janssen). Int J Dermatol. 1990;29:661–2.
11. Al-Fouzan A, Al Saleh Q, Najem M, et al. Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole. Int J Dermatol. 1991;30:519-21.
12. Paradisi M, Grosso MG, Angelo C, et al. A pediatric case of lupoid leishmaniasis diagnosed by PCR. Minerva Pediatr. 2001;53:33-7.
13. Hay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol. 1999;141:36-40.
14. Rodríguez LV, Dedet JP, Paredes V, et al. A randomized trial of amphotericin B alone or in combination with itraconazole in treatment of mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz. 1995;90:525-8.
15. Marovich MA, Lira R, Shepard M, et al. Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin Infect Dis. 2001;33(7):1076-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Tauseef Kamran
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
